18 (23.7%) and 22 (28.9%) patients in the 24- and 48-week groups (P = 0.46), respectively, required dose reduction
PEG-IFN α-2a - 24 weeks
PEG-IFN α-2a - 48 weeks
subcutaneous injections of erythropoietin - patients with chronic hepatitis C with HCV genotype 6